NOVARTIS AG NAMENS-AKTIEN SF 0,5
NOVARTIS AG NAMENS-AKTIEN SF 0,5/ CH0012005267 /
904278
01/08/2024 10:29:41
|
Var.
+0.360
|
Volume |
Denaro10:29:41 |
Lettera10:29:41 |
Capitalizzazione di mercato |
Dividend Y. |
Rapporto P/E |
103.140EUR
|
+0.35%
|
- Fatturato: - |
103.140Quantità in denaro: - |
103.580Quantità in lettera: - |
235.54 bill.EUR |
- |
- |
Descrizione business
Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, cost-saving generic and biosimilar pharmaceuticals and eye care. Novartis has leading positions globally in each of these areas. Novartis products are sold in approximately 155 countries around the world.
Consiglio di amministrazione & Consiglio di sorveglianza
CEO |
Vasant Narasimhan, M.D. |
Consiglio di amministrazione |
Harry Kirsch, Dr. Klaus Moosmayer, Dr. Steffen Lang, Karen L. Hale, Marie-France Tschudin, Rob Kowalski, Shreeram Aradhye, Victor Bulto, Aharon (Ronny) Gal, Dr. Fiona H. Marshall |
Consiglio di sorveglianza |
Dr. Joerg Reinhardt, Bridgette Heller, Charles L. Sawyers, M.D., Dr. Charlotte Pamer-Wieser, Dr. Nancy C. Andrews, Elizabeth Doherty, Frans van Houten, Patrice Bula, Simon Moroney, Ton Buechner, William T. Winters, Daniel Hochstrasser, Ana de Pro Gonzalo, John D. Young |
Dati aziendali
Name: |
Novartis AG |
Indirizzo: |
Lichtstrasse 35,CH-4002 Basel |
Telefono: |
+41-61-324-1111 |
Fax: |
+41-61-324-8001 |
E-mail: |
-
|
Internet: |
www.novartis.com |
Industria: |
Healthcare |
Settore: |
Pharmaceutical Industry |
Sub settore: |
Pharmaceuticals |
Fine dell'anno finanziario: |
31/12 |
Flottante libero: |
86.85% |
Data dell'IPO: |
07/03/1996 |
Company calendar
CW 44 | 29/10/2024
Interim Report 3rd Quarter/9 Months
|